Sep 17 |
Gilead Sciences (GILD) Stock Sinks As Market Gains: Here's Why
|
Sep 16 |
This 'forgotten child' is one of the best biotech plays: Analyst
|
Sep 16 |
Gilead’s lenacapavir: HIV prospects strongest in long-acting combos with Merck’s islatravir
|
Sep 14 |
Should You Be Worried About Gilead Sciences, Inc.'s (NASDAQ:GILD) 5.7% Return On Equity?
|
Sep 14 |
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
|
Sep 14 |
Insider Sale: Johanna Mercier Sells 29,357 Shares of Gilead Sciences Inc (GILD)
|
Sep 13 |
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
|
Sep 13 |
Subcutaneous Tecentriq gets FDA OK; Gilead shot succeeds in second HIV trial
|
Sep 12 |
Why Gilead Sciences Stock Thrashed the Market Today
|
Sep 12 |
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
|